本报记者 杨笑寒 今年以来，险企"补血"进程持续加快。据《证券日报》记者统计，截至6月22日，年内险企通过增资、发债方式补充资本 合计达692.13亿元（部分境外发行债券规模按发稿日汇率换算，下同），同比增长95%。 对于险企"补血"规模大幅增加的原因，普华永道管理咨询（上海）有限公司中国金融行业管理咨询合伙人周瑾对《证券日 报》记者表示，一是因为近年实施的偿二代二期工程对资本认定更加严格，使得众多保险公司的偿付能力充足率出现下降，亟 须通过增资或发债等方式来补充资本；二是利率持续下行会对保险公司的责任准备金和偿付能力充足率持续加压，为了维持偿 付能力水平充足以支撑业务发展，保险公司仍需要通过股东增资和发行资本补充债等方式进行外生性的资本补充。 南开大学金融学教授田利辉补充说，当前保险行业进入深度调整和转型阶段，保险公司也需要通过资本补充来增强竞争力 和风险防范能力。 此外，保险行业还探索境外零息可转债、资本公积金转增注册资本等多元化资本补充方式。 近日，中国平安发布公告称，此前其拟发行约117.65亿港元于2030年到期的零息可转换为本公司H股股份的债券（以下简 称"H股可转换债券"）。6月11日，H股可转 ...

本报记者 杨洁 6月22日，内地与香港快速支付系统互联互通（以下简称"跨境支付通"）正式上线。《证券日报》记者获悉，作为境内首 批试点行，多家银行积极落地跨境支付通业务，为内地和香港两地居民提供跨境实时汇款服务。 业内人士表示，跨境支付通不仅解决了传统跨境支付的效率与成本痛点，更成为推动人民币国际化、深化内地与香港金融 合作的战略抓手。下一步，商业银行可以以跨境支付通为切入点，加速技术迭代和优化服务模式，为中国金融开放和全球支付 体系变革贡献力量。 助力金融高水平开放 "随着内地与香港往来日益密切，经贸合作更加频繁，居民南下北上消费需求旺盛，对跨境支付的高效安全以及资金的快 速流通提出了更高要求。"中国人民银行有关部门负责人在答记者问时表示，中国人民银行聚焦跨境支付需求，联合香港金融 管理局开展内地网上支付跨行清算系统与香港快速支付系统"转数快"互联互通，充分发挥监管合力和系统优势，打通资金清算 渠道，提高支付效率、降低交易成本，促进两地经贸活动与人员往来，助力金融高水平开放，进一步巩固和提升香港国际金融 中心地位。 据悉，与传统跨境汇款相比，跨境支付通有效缩短了跨境汇款链路，提高了跨境汇款效率，从技术上支持 ...

Core Viewpoint - The recent draft of the "Securities Company Classification Evaluation Regulations" aims to shift the focus of the industry from "scale competition" to "quality competition," promoting differentiated development paths for small and medium-sized institutions [1][2] Group 1: Industry Role and Function - Securities firms play a crucial role in China's capital market and financial system, facilitating a healthy investment and financing cycle, serving the real economy, national strategies, and wealth management for residents [1] - The classification results show a stable number of firms across categories, with A, B, and C class companies accounting for 50%, 40%, and 10% respectively, and approximately 14 firms maintaining an AA rating [1] Group 2: Regulatory Changes and Focus - The revised regulations emphasize guiding securities firms to enhance their functional roles and professional capabilities, with a new evaluation framework focusing on risk management, compliance, business development, and functional performance [2] - A new "functional performance" evaluation organized by the China Securities Association will be incorporated into the classification evaluation to better assess firms' contributions [2] Group 3: Business Development and Performance Metrics - The regulations remove the revenue-based scoring system and increase the emphasis on net asset return, raising the maximum score from 1 to 2 points, encouraging firms to focus on efficiency and quality rather than just scale [4][5] - The projected net asset return for the securities industry in 2024 is 5.5%, a 0.7 percentage point increase year-on-year, with firms like Dongfang Caifu leading at 12.6% [4] Group 4: Differentiated Development for Small and Medium-sized Firms - The regulations expand the scoring criteria for net asset return and major business income from the top 20 to the top 30 firms, allowing smaller firms to explore differentiated development paths [5] - Small and medium-sized firms are encouraged to focus on high-end wealth management and specific industry sectors to create specialized advantages and provide tailored financing solutions [5][6] Group 5: Encouragement of Long-term Investment - The regulations also introduce new indicators to promote long-term capital inflow, including metrics for self-investment in equity assets and management of equity fund products, encouraging firms to enhance their contributions to long-term wealth management [6]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trials and the safety of its gene therapy product RP-A501 [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc. and covers purchasers of Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025 [1]. - The lawsuit alleges that Rocket Pharmaceuticals provided misleading information regarding the safety and clinical trial protocol of RP-A501, particularly concerning serious adverse events, including participant deaths [3][4]. - On May 27, 2025, the U.S. FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a serious adverse event, which was not disclosed to investors prior to the protocol amendment [4]. Group 2: Lead Plaintiff Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [5]. - The lead plaintiff is typically the investor with the greatest financial interest in the case and can select a law firm to litigate the lawsuit [5]. Group 3: Company Background - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare diseases [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

哈梅内伊高级顾问：即便核设施被摧毁 游戏也远未结束 智通财经6月23日电，据央视新闻，伊朗最高领袖哈梅内伊的高级顾问阿里·沙姆哈尼当地时间22日傍晚 在社交媒体上发文称，即使伊朗核设施被摧毁，游戏也远未结束。浓缩（铀）材料、知识储备和政治意 志依然存在。"凭借正当防卫权，善于谋略、避免盲目打击的一方将掌握政治与行动主动权。好戏还在 后头！"6月13日，沙姆哈尼在以军对伊朗的袭击中受重伤，此后有媒体报道称其已于14日死亡。6月21 日，沙姆哈尼本人在社交媒体上发文否认身亡传闻。 ...

Core Insights - The global obesity drug market is projected to exceed $100 billion by 2030, driven by the increasing number of obese individuals worldwide [1][2] - Major pharmaceutical companies, both multinational and domestic, are intensifying their efforts in the obesity drug sector, leading to fierce competition in technology, capital, and market presence [2] Domestic Drug Development - Domestic companies are making significant progress in the development of obesity drugs, with recent approvals for clinical trials of GLP-1 class innovative drugs by Changshan Biochemical Pharmaceutical and Guangdong Zhongsheng Pharmaceutical [3] - Changshan Biochemical has received approval for clinical trials of its injection for weight loss, while Guangdong Zhongsheng has completed the first participant enrollment for its innovative peptide drug RAY1225 in a Phase III trial [3] - The global sales of GLP-1 receptor agonists (GLP-1RA) are expected to exceed $150 billion by 2031, indicating a strong market potential [3] Market Dynamics - The global obesity drug market is currently dominated by Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, with semaglutide projected to generate sales of 6.6 billion yuan in China by 2024 [4] - The domestic GLP-1 drug market is expected to surpass 20 billion yuan by 2030, with several domestic GLP-1 drugs already approved [5] - The influx of domestic companies into the obesity drug market reflects a consensus on the explosive growth potential of the sector, although it may lead to intensified price competition [5] Competitive Landscape - Chinese pharmaceutical companies are leveraging multi-target innovation and differentiated development strategies to gain a competitive edge in the GLP-1 market [6] - Jiangsu Hengrui Medicine's dual-target drug HRS9531 has shown superior weight loss results compared to existing treatments, indicating the potential for domestic products to compete internationally [6] - Cross-border collaborations in the GLP-1 field are increasing, with companies like Federated Pharmaceutical and Hansoh Pharmaceutical engaging in licensing agreements to expand their market reach [6][7] Future Outlook - The obesity drug market is expected to undergo a significant reshuffle in the next 3 to 5 years, with products that demonstrate clinical value and technological barriers likely to prevail [7]

本报记者 袁传玺 近日，国际数据公司IDC发布的《中国2024年AI数字人市场份额》报告显示，2024年中国AI数字人市场规模约41.2亿元， 同比增长85.3%，实现高速增长。 国内AI数字人市场的高速增长，离不开技术的进步。在生成式AI与大模型技术浪潮下，2025年，AI数字人正以前所未有的 速度从概念走向规模化应用，成为产业数字化转型进程中的焦点与新引擎。 百度集团股份有限公司（以下简称"百度"）副总裁、电商总经理平晓黎表示，今年4月份百度发布的高说服力数字人已让 数字人进入3.0时代，标志着智能电商迈入新篇章，新一代高说服力数字人成为了一个"形神音容"高度协调、会思考决策、能协 作完成特定任务的超级智能体。 AI数字人加速普及 以百度高说服力数字人为例，百度研制的多模协同的数字人技术，基于文心4.5T实现了融合多模规划与深度思考的剧本生 成，由剧本驱动数字人多模协同，实现动态决策的实时交互，使数字人的"神、形、音、容、话"达到高度统一，最终呈现出一 个具备高表现力、内容吸引人、"人—物—场"可自由交互的超拟真数字人。 平晓黎表示，百度的罗永浩数字人已达到媲美头部主播的体感效果，随着大模型与多模能力发展 ...

本报记者 田鹏 日前，上海数据交易所与上海交通大学上海高级金融学院在中国企业数据价值化高峰论坛上共同发布"上市公司数据价值 化研究榜单"，为市场提供全新的、前瞻性的评价视角。作为国内首个系统性评价上市公司数据价值化进程的研究成果，榜单 分为数据资源入表上市公司100强和数据资源未入表上市公司100强，同时按照行业、地区等维度做了区分。 "本次榜单的发布有助于明晰数据资产化的发展方向，为行业实践提供重要参考与指引。"上海数据交易所总经理汤奇峰在 接受《证券日报》记者采访时表示，通过榜单不仅能够识别出在数据资产化工作中处于领先地位的企业，还能借此剖析其面临 的挑战，为其他企业未来的发展提供可借鉴的示范路径。同时，鉴于上市公司在市场中具有重要的标杆作用，该榜单亦从侧面 反映了作为中国数字经济重要主体的上市公司在推动数字经济发展中的贡献，以及其在数据要素化、产品化和资产化过程中的 发展情况。 值得关注的是，此次发布的榜单不仅对已实现数据资产入表企业的价值化程度进行了评估，还特别评选出100家未入表企 业的数据价值化程度，以便更全面地洞察整个市场在数据价值化进程中的发展态势。 榜单结果显示，万达信息股份有限公司（以下简 ...

Group 1 - The article discusses the author's journey into investing, starting in high school in 2011, focusing on REITs, preferred stocks, and high-yield bonds, indicating a long-standing interest in markets and the economy [1] - The author has recently adopted a strategy that combines long stock positions with covered calls and cash secured puts, emphasizing a fundamental long-term investment approach [1] - The author primarily covers REITs and financials on Seeking Alpha, with occasional articles on ETFs and other stocks influenced by macro trade ideas [1]

6月20日，深圳市龙岗区坪地街道举办2025年"校企联谊"人才培养引进合作交流活动，以深化辖区企业与全国各地院校的长期合作机制，为经济高质量发展 提供人才支撑。活动邀请了湖南理工学院、大连工业大学等13家院校代表，深圳市建滔科技有限公司、深圳市杰科数码有限公司等24家坪地重点企业参加。 下午的座谈会上，街道党工委副书记、人大工委主任薛荣喜介绍了坪地街道概况及产业发展中对实用型技能人才的迫切需求。坪地街道始终致力于为人才营 造优质的生活与发展环境，助力企业扎根坪地、发展壮大。此次"校企联谊"活动旨在畅通人才供需两端，拓宽人才共育共引通道，通过加强校企合作交流， 为辖区企业高效精准输送高素质技术技能人才，为院校毕业生搭建优质就业创业平台，最终实现校、企、地三方发展共赢。 在随后的自由洽谈环节，校企双方围绕人才培养、技术合作、产学研一体化等议题展开了深入交流讨论。双方展现出强烈的合作意向，明确了彼此需求与合 作方向。现场交流气氛活跃，双方互加微信、积极对接，现场共签订合作协议24份。此外，部分院校代表还热情邀请坪地企业赴校开展招聘宣讲等活动。 龙岗区人力资源服务中心副主任张伟球详细介绍了龙岗区的经济发展概况、创新活 ...